Trial · NCT02921737
TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)
NCT02921737, Phase 2, Terminated, University of Florida; results first posted 2021-02-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003). Trials, record NCT02921737. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02921737
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)
- NCT number
- NCT02921737
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- University of Florida
- Conditions
- Pancreatic Cancer
- Interventions
- TAS-102
- First posted
- 2016-10-03
- Last updated
- 2021-02-04
- Results first posted
- 2021-02-04
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | up to 54 weeks | To determine the progression free survival (PFS), which is defined as the duration of time from study entry to disease progression, death, or the date of last contact, whichever occurred first. Subjects were not included in the data for this outcome measure if they went off study for reasons other than disease progression, death or being lost to follow-up. |
| Secondary | Objective Response Rate (ORR) | 6 months | To determine the objective response rate (ORR) by RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.1 criteria. ORR is defined as the percentage of subjects who attained either a complete or partial response (CR + PR) by RECIST v1.1 criteria. RECIST v1.1 criteria defines a partial response (PR) as a decrease of the sum of the largest diameters of each target lesion by at least 30%. A complete response (CR) is defined as the disappearance of all target lesions (except lymph nodes, whose short axis must measure 10 mm or less). |
| Secondary | Clinical Benefit Rate | 6 months | To determine the Clinical Benefit Rate, defined as the percent of evaluable subjects who achieved either a complete or partial response or stable disease per RECIST v1.1 criteria. RECIST v1.1 criteria defines a partial response as a decrease of the sum of the largest diameter of each target lesion by at least 30%. A complete response is defined as the disappearance of all target lesions (except lymph nodes, whose short axis must measure 10 mm or less). By RECIST v1.1 criteria, a subject is considered to have stable disease when the sum of the largest diameter of the target lesions has neither decreased enough to qualify as a partial response not increased enough to qualify as progressive disease. |
| Secondary | Time to Progression (TTP) | up to 54 weeks | To determine the time to progression (TTP), defined as the duration of time from study entry to disease progression |
| Secondary | Overall Survival (OS) | up to 84 weeks | To determine overall survival (OS), defined as the duration of time from study entry to time of death. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression Free Survival (PFS) | up to 54 weeks | Only 6 subjects met the criteria to be included in the data for this endpoint. | weeks | MEAN |
| SECONDARY | Objective Response Rate (ORR) | 6 months | Only two subjects were considered evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Clinical Benefit Rate | 6 months | Only two subjects were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time to Progression (TTP) | up to 54 weeks | Disease progression only occurred for 5 subjects. | weeks | MEAN |
| SECONDARY | Overall Survival (OS) | up to 84 weeks | weeks | MEAN |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Treatment Arm | 13.64 | Full Range 0.14 to 53.86 | weeks | |
| Objective Response Rate (ORR) | Treatment Arm | 0 | Participants | ||
| Clinical Benefit Rate | Treatment Arm | 1 | Participants | ||
| Time to Progression (TTP) | Treatment Arm | 15.43 | Full Range 0.14 to 53.86 | weeks | |
| Overall Survival (OS) | Treatment Arm | 23.45 | Full Range 4.71 to 83.29 | weeks |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment Arm | 7 | |
| Overall Study | COMPLETED | Treatment Arm | 7 | |
| Overall Study | NOT COMPLETED | Treatment Arm | 0 |
Source ClinicalTrials.gov
Adverse events22
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Treatment Arm | 3 | 7 | |
| other | Alkaline phophatase increased | Investigations | Treatment Arm | 1 | 7 | |
| other | Anemia | Blood and lymphatic system disorders | Treatment Arm | 1 | 7 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Treatment Arm | 1 | 7 | |
| other | Chills | General disorders | Treatment Arm | 1 | 7 | |
| other | Constipation | Gastrointestinal disorders | Treatment Arm | 2 | 7 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Treatment Arm | 1 | 7 | |
| other | Diarrhea | Gastrointestinal disorders | Treatment Arm | 3 | 7 | |
| other | Dizziness | Nervous system disorders | Treatment Arm | 1 | 7 | |
| other | Edema limbs | General disorders | Treatment Arm | 1 | 7 |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment Arm | 7 | 7 |
| Total, other adverse events | Treatment Arm | 6 | 7 |
| Total, serious adverse events | Treatment Arm | 2 | 7 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02921737
GET https://conductscience.org/api/trials/v1/NCT02921737/events?page=2